Table 3.

Adjusted odds ratios (95% CI) of the association between CLL incidence and ever-use of statins, excluding the year before the index date

Ever-use of statinsModel AaModel Bb
Any statin0.94 (0.82–1.08)0.89 (0.76–1.04)
Hydrophilicc1.14 (0.93–1.41)1.08 (0.86–1.34)
 Pravastatind1.18 (0.89–1.55)1.13 (0.84–1.51)
 Rosuvastatind1.12 (0.85–1.47)1.06 (0.79–1.42)
High-potency lipophilicc0.96 (0.82–1.12)0.94 (0.79–1.11)
 Simvastatind1.02 (0.82–1.27)1.03 (0.82–1.29)
 Atorvastatind0.99 (0.84–1.18)0.96 (0.80–1.16)
Low-potency lipophilicc0.68 (0.48–0.96)0.64 (0.45–0.92)
 Fluvastatind0.72 (0.41–1.25)0.71 (0.40–1.26)
 Lovastatind0.70 (0.47–1.06)0.66 (0.43–1.02)
  • aModel A includes the matching variables (age, gender, residence, and duration of coverage).

  • bModel B includes the matching variables, chronic cardiovascular disease (excluding hypertension), income quintile, number of physician visits 5 years before index date, ever-use of non-statin lipid-lowering drugs, non-aspirin NSAIDs and aspirin and derivatives.

  • cAlso adjusted for ever-use of the other statin subgroups.

  • dAlso adjusted for ever-use of the other individual statins.